JPWO2020148530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020148530A5 JPWO2020148530A5 JP2021541187A JP2021541187A JPWO2020148530A5 JP WO2020148530 A5 JPWO2020148530 A5 JP WO2020148530A5 JP 2021541187 A JP2021541187 A JP 2021541187A JP 2021541187 A JP2021541187 A JP 2021541187A JP WO2020148530 A5 JPWO2020148530 A5 JP WO2020148530A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- peptide ligand
- amino acid
- sar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 239000003446 ligand Substances 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 12
- 229960002685 biotin Drugs 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002062 molecular scaffold Substances 0.000 description 2
- GHITVUOBZBZMND-UHFFFAOYSA-N 1,3,5-tris(bromomethyl)benzene Chemical compound BrCC1=CC(CBr)=CC(CBr)=C1 GHITVUOBZBZMND-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000052645 human CD38 Human genes 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical group CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1900530.5 | 2019-01-15 | ||
| GBGB1900530.5A GB201900530D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for CD38 |
| PCT/GB2020/050074 WO2020148530A1 (en) | 2019-01-15 | 2020-01-15 | Bicyclic peptide ligands specific for cd38 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517399A JP2022517399A (ja) | 2022-03-08 |
| JP2022517399A5 JP2022517399A5 (https=) | 2023-01-25 |
| JPWO2020148530A5 true JPWO2020148530A5 (https=) | 2023-01-25 |
Family
ID=65528178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541187A Pending JP2022517399A (ja) | 2019-01-15 | 2020-01-15 | Ｃｄ３８に特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220133733A1 (https=) |
| EP (1) | EP3911366A1 (https=) |
| JP (1) | JP2022517399A (https=) |
| CN (1) | CN113597317A (https=) |
| GB (1) | GB201900530D0 (https=) |
| WO (1) | WO2020148530A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| US12551567B2 (en) | 2018-12-21 | 2026-02-17 | Bicyclerd Limited | Bicyclic peptide ligands specific for PD-L1 |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| IL300248A (en) | 2020-08-03 | 2023-03-01 | Bicycletx Ltd | peptide-based linkers |
| GB202016331D0 (en) * | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| CN118388598A (zh) * | 2024-04-22 | 2024-07-26 | 苏州大学附属第一医院 | 标记前体、探针及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006514104A (ja) * | 2002-12-12 | 2006-04-27 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． | グリコーゲンシンターゼキナーゼ−３阻害剤 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| DK1844337T3 (da) | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| AU2009211253B2 (en) | 2008-02-05 | 2014-11-06 | Bicyclerd Limited | Methods and compositions |
| EP3613426A1 (en) * | 2014-05-21 | 2020-02-26 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド |
| JP2018521960A (ja) * | 2015-04-28 | 2018-08-09 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | 酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤 |
| JP7301757B2 (ja) * | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| GB201810320D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
-
2019
- 2019-01-15 GB GBGB1900530.5A patent/GB201900530D0/en not_active Ceased
-
2020
- 2020-01-15 WO PCT/GB2020/050074 patent/WO2020148530A1/en not_active Ceased
- 2020-01-15 JP JP2021541187A patent/JP2022517399A/ja active Pending
- 2020-01-15 CN CN202080021078.5A patent/CN113597317A/zh active Pending
- 2020-01-15 US US17/422,943 patent/US20220133733A1/en not_active Abandoned
- 2020-01-15 EP EP20701838.3A patent/EP3911366A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020148530A5 (https=) | ||
| JP2025011099A5 (https=) | ||
| JP4173913B2 (ja) | Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法 | |
| JP5954736B2 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
| JP7039574B2 (ja) | 放出制御ｐｔｈ化合物の漸増用量設定 | |
| JP2023029957A (ja) | 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 | |
| JPWO2021019244A5 (https=) | ||
| JP2005511503A5 (ja) | 過剰体重を防止または治療するためのオキシントモジュリン | |
| JPWO2020128527A5 (https=) | ||
| JPWO2020148526A5 (https=) | ||
| TW201028162A (en) | Amide based glucagon superfamily peptide prodrugs | |
| KR20190062496A (ko) | 조절 방출 pth 화합물을 위한 투여 용법 | |
| JP2016518351A5 (https=) | ||
| JPWO2020148525A5 (https=) | ||
| JPWO2021019243A5 (https=) | ||
| JPWO2020120981A5 (https=) | ||
| KR20220128390A (ko) | 부갑상선기능저하증 치료 | |
| JPWO2020120980A5 (https=) | ||
| JPWO2020148528A5 (https=) | ||
| FI3746467T3 (fi) | Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö | |
| JP2019527053A5 (https=) | ||
| JPWO2020120984A5 (https=) | ||
| CN106164088A (zh) | 长效肾上腺髓质素衍生物 | |
| JPWO2020120983A5 (https=) | ||
| JPWO2020148529A5 (https=) |